Concepedia

Nathan B. Mantlo

NB

Statistics

Publications

34

Citations

2.1K

H-Index

24

Active since

1982

Affiliations

Eli Lilly (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

United States Military Academy

Utah State University

Nathan B. Mantlo is an author at Eli Lilly (United States) specializing in pharmacology, medicinal chemistry, and medicine.

Publications per year

1982–2015

34

Publications

34

Molecular Cloning and Characterization of a Novel p38 Mitogen-activated Protein Kinase

Xuhong Sunny Wang, Katrina Diener, Carl L. Manthey et al. · Journal of Biological Chemistry · 1997 · 334 citations · Full text

, , +13

Potent, orally absorbed glucagon receptor antagonists

Stephen E. de Laszlo, Candice Hacker, Bing Li et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 169 citations · Full text

, , +12

Potent, orally active imidazo[4,5-b]pyridine-based angiotensin II receptor antagonists

Nathan B. Mantlo, Prasun K. Chakravarty, Debra L. Ondeyka et al. · Journal of Medicinal Chemistry · 1991 · 161 citations · Full text

, , +9

Pyrroles and other heterocycles as inhibitors of P38 kinase

Stephen E. de Laszlo, Denise M. Visco, Lily Agarwal et al. · Bioorganic & Medicinal Chemistry Letters · 1998 · 119 citations · Full text

, , +11

Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure

Guoqing Cao, Thomas P. Beyer, Youyan Zhang et al. · Journal of Lipid Research · 2011 · 115 citations · Full text

, , +16

1–5 of 34